REDUCTION IN CONTROLLED ATTENUATION PARAMETER AND LIVER STIFFNESS WITH SAROGLITAZAR IN NAFLD: A PROSPECTIVE ANALYSIS
DOI:
https://doi.org/10.56802/y0zhqk37Keywords:
NAFLD, liver Stiffness, CAP, lipid profile, saroglitazarAbstract
Background: Non-Alcoholic Fatty Liver Disease (NAFLD) is defined as the accumulation of fat
in the liver, typically affecting more than 5% of hepatocytes, in the absence of significant alcohol
consumption. NAFLD is considered the most common liver disease in the developed world and is fast emerging as a global health priority due to the epidemic burden of obesity, diabetes, and metabolic diseases worldwide.
Objective: The purpose of the study was to analyze the reduction in controlled attenuation parameter and liver stiffness with Saroglitazar in NAFLD.
Material and method: After an overnight fast, all 240 study participants provided blood samples in accordance with the protocol for the measurement of serum lipids and lipoproteins. The lipid profile and liver stiffness and CAP parameters were assessed. The patients on continued saroglitazar 4 mg once daily therapy was follow-up at 24 and 52 weeks. SPSS version 20 was used for the statistical analysis, and p<0.05 was chosen as the significance level.
Result: Among 240 patients, there was significant decrease in Continued Attenuation Parameter (CAP) – baseline 333.68 ± 28.21db/m, at 24 weeks 300.40± 25.52db/m and at 52 weeks 286.89± 24.22db/m. Similarly, there was significant decrease in Liver Stiffness Measurement (LSM) also baseline 8.26 ± 2.73kPa, at 24 weeks 7.73± 2.56kPa and at 52 weeks 7.15± 2.31kPa. A shift toward milder fibrosis stages was evident: F0–F1 rose from 32.081% to 48.8% (P = 0.004), F2 fibrosis reduce from 48.33% to 43.33%, F3 fibrosis reduce by 17.08% to 12.92%, while F4 nearly resolved. These findings reflect plausible reductions in fibrosis burden over time and parallel trends from other 52-week observational cohorts.
Conclusion: These findings suggest that saroglitazar 4 mg daily may be a promising therapeutic option for non-diabetic NAFLD patients, providing multi-dimensional benefits across liver stiffness and fibrosis.
